Clostridioides Difficile: A Clinical Update

Greta Safoncik, 3rd Year Medical Student, Lancaster University
Guilherme Movio, 4th Year Medical Student, Lancaster University

CLOSTRIDIOIDES DIFFICILE

Clostridioides Difficile (C. Difficile) is a gram-positive spore-forming toxin-producing anaerobic bacillus. It can survive on surfaces for a long period of time by forming heat, acid, and alcohol resistant spores. The bacteria colonise the bowel of 3-5% of the adult population and 20% of hospitalised patients. It is transmitted between individuals through a fecal-oral route. Asymptomatic carriers, infected patients and contaminated surfaces can act as a reservoir for spores. C. Difficile is currently one of the major nosocomial infections.1

PATHOPHYSIOLOGY

The pathophysiology of C. Difficile can be divided into three phases. The first phase of the pathogenesis involves the suppression of the normal, protective microbiota of the intestines. Clinically, this usually occurs secondary to antibiotic treatment, commonly due to clindamycin, ciprofloxacin, cephalosporin and fluoroquinolones. This allows for optimum conditions for C. Difficile to thrive when ingested. This leads to C. Difficile spore germination and toxin-producing cell formation which causes inflammation and consequently an immune response (second phase of pathogenesis).2 The pathogen does not invade the epithelium; its virulence is through enzymes and toxins. The main toxins produced are ToxA and ToxB, which disrupt the cytoskeleton of the colonic epithelial cells. This leads to the dissociation of tight junctions between colonic epithelial cells, fluid secretion, neutrophil infiltration and cytokine production. Influx of neutrophils into the mucosa cause pseudomembrane formation, classically seen on endoscopy as yellow-white nodules or plaques. Histologically, this is seen as “volcano” lesions containing neutrophils and fibrin.3,4 The third phase involves the potential for the infection to reoccur as a result of the antibiotic treatment for C. Difficile. This is when the antibiotic levels do not completely inhibit C. Difficile spores. Since antibiotics target both C. Difficile and normal gut microflora, there is a potential for spores to cause recurrent infection until the disrupted colonic microflora is recovered.2

RISK FACTORS

Risk factors for C. Difficile infection include; antibiotic use (clindamycin and 2nd/3rd generation cephalosporins), prolonged hospital stay, age over 65, previous C. Difficile infection, comorbidities, use of proton pump inhibitors, immunocompromised patients and inflammatory bowel disease.5,6

CLINICAL SIGNS

The hallmark of C. Difficile infection is a new onset watery diarrhea. Blood can be present, but overt bleeding is rare. Other features include abdominal pain, fever and raised white cell count (WCC). In severe cases hypotension, tachycardia, raised creatinine and lactate may develop. This is shown in Table 1.1,7

DIAGNOSES

C. Difficile infection is suspected clinically and confirmed with stool testing. The three main stool tests for C. Difficile detection used in the National Health Service are toxin enzyme immunoassays (EIAs), toxin gene (NAAT or PCR) and glutamate dehydrogenase (GDH) EIA. The Department of Health recommends a two-step process for diagnoses.8

Table 1. Summarizing the clinical features of the different severities of C. Difficile infection5

<table>
<thead>
<tr>
<th>Mild</th>
<th>Moderate</th>
<th>Severe</th>
<th>Life-Threatening</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal WCC</td>
<td>WCC raised but &lt;1.5x10^9/l</td>
<td>WCC raised &gt;1.5x10^9/l</td>
<td>Hypotension</td>
</tr>
<tr>
<td>Stool frequency &lt;3 per day</td>
<td>Stool frequency 3-5 per day</td>
<td>Acute rise in creatinine (more than 50% of baseline)</td>
<td>Partial or complete ileus</td>
</tr>
<tr>
<td>Stool consistency type 5-7 on Bristol Stool Form Scale</td>
<td>Temperature above 38.5°C</td>
<td>Toxic megacolon</td>
<td></td>
</tr>
<tr>
<td>Evidence of severe colitis (examination and image)</td>
<td>Radiological evidence of severe disease</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Step 1. NAAT or (GHD) EIA

Step 2. For samples that test positive, toxin EIA should follow, as presence of toxin detects current C. Difficile infection.
MANAGEMENT

Updated NICE guidelines on the management of *C. Difficile* for adults aged 18 years and over were published in July 2021 and are summarised in Table 2.  

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Antibiotic, dosage and course length</th>
</tr>
</thead>
<tbody>
<tr>
<td>First-line antibiotic for the first episode of mild, moderate or severe <em>C. Difficile</em> infection</td>
<td>Vancomycin 125mg orally four times a day for 10 days</td>
</tr>
<tr>
<td>Second-line antibiotic for first episode of mild, moderate or severe <em>C. Difficile</em> infection if Vancomycin is ineffective</td>
<td>Fidaxomicin 200mg orally twice a day for 10 days</td>
</tr>
<tr>
<td>Antibiotics for <em>C. Difficile</em> infections if first/second line antibiotics are ineffective</td>
<td>Seek specialist advice. Specialist may offer: Vancomycin up to 500mg orally four times a day for 10 days, with or without Metronidazole 500mg intravenously three times a day for 10 days</td>
</tr>
<tr>
<td>Antibiotic for a further episode of <em>C. Difficile</em> infection within 12 weeks of symptom resolution (relapse)</td>
<td>Fidaxomicin 200mg orally twice a day for 10 days</td>
</tr>
<tr>
<td>Antibiotics for a further episode of <em>C. Difficile</em> infection more than 12 weeks after symptom resolution (recurrence)</td>
<td>Vancomycin: 125mg orally four times a day for 10 days OR Fidaxomicin: 200mg orally twice a day for 10 days</td>
</tr>
<tr>
<td>Antibiotics for life-threatening <em>C. Difficile</em> infection</td>
<td>Seek urgent specialist advice, which may include surgery. Antibiotics that specialists may initially offer are: Vancomycin: 500mg orally four times a day for 10 days With Metronidazole: 500mg intravenously three times a day for 10 days</td>
</tr>
</tbody>
</table>

Table 2. Summary of NICE guidelines on the management of *C. Difficile*  

ACKNOWLEDGEMENTS

We would like to thank Zuzanna Nowinka (6th Year Medical Student), for her illustration for this piece.

Correspondence to:
g.movio@lancaster.ac.uk
g.safoncikova@lancaster.ac.uk

REFERENCES